SGCG and Hypercholesterolemia: While not specifically tested in this study, it is possible that TG101348 reduces atherogenesis by suppressing type I and type II cytokine receptor–mediated pro-inflammatory responses in the setting of hypercholesterolemia in Apoe−/− mice, in addition to reversal of leukocytosis, including acting directly on macrophages [45].